Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

被引:16
|
作者
Schneider, Andreas [1 ,2 ]
Schneider, Markus P. [2 ,3 ]
Scharnagl, Hubert [4 ]
Jardine, Alan G. [2 ]
Wanner, Christoph [1 ]
Drechsler, Christiane [1 ]
机构
[1] Univ Hosp Wuerzburg, Div Nephrol, Dept Med, Wurzburg, Germany
[2] Univ Glasgow, Inst Cardiovasc & Med Sci, Renal Res Grp, British Heart Fdn BHF,Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[3] Univ Hosp Erlangen, Dept Nephrol & Hypertens, Erlangen, Germany
[4] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria
关键词
STIMULATING AGENTS; ANEMIA; HEMOGLOBIN; PROTEIN; DISEASE;
D O I
10.1186/1471-2369-14-67
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients. Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers. Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance. Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies. Clinical trial registration: The study was registered at the German medical authority (BfArM; registration number 401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The Efficacy of Short-Term Toe Resistance Training in Chronic Hemodialysis Patients with Type 2 Diabetes
    Kataoka, Hiroaki
    Miyatake, Nobuyuki
    Matsuda, Naoko
    Hikasa, Yasuaki
    Kitayama, Naomi
    Nagai, Shion
    Tanaka, Satoshi
    HEALTHCARE, 2023, 11 (01)
  • [22] Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis
    Maurizio Gallieni
    Cristina De Salvo
    Maria Elena Lunati
    Antonio Rossi
    Francesca D’Addio
    Ida Pastore
    Gianmarco Sabiu
    Roberta Miglio
    Gian Vincenzo Zuccotti
    Paolo Fiorina
    Acta Diabetologica, 2021, 58 : 975 - 981
  • [23] Glucose variability in maintenance hemodialysis patients with type 2 diabetes
    Fackovcova, Lucia
    Barlovic, Drazenka Pongrac
    Broz, Jan
    HEMODIALYSIS INTERNATIONAL, 2023, 27 (04) : 475 - 476
  • [24] Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    Wanner, C
    Krane, V
    März, W
    Olschewski, M
    Mann, JFE
    Ruf, G
    Ritz, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (03): : 238 - 248
  • [25] Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis
    Gallieni, Maurizio
    De Salvo, Cristina
    Lunati, Maria Elena
    Rossi, Antonio
    D'Addio, Francesca
    Pastore, Ida
    Sabiu, Gianmarco
    Miglio, Roberta
    Zuccotti, Gian Vincenzo
    Fiorina, Paolo
    ACTA DIABETOLOGICA, 2021, 58 (08) : 975 - 981
  • [26] Resistance training in patients with type 2 diabetes
    Holt, R
    DIABETES OBESITY & METABOLISM, 2003, 5 (01): : 68 - 68
  • [27] Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes
    Nakamura, T
    Ushiyama, C
    Osada, S
    Shimada, N
    Ebihara, I
    Koide, H
    RENAL FAILURE, 2001, 23 (06) : 863 - 864
  • [28] Plasma Concentration of Pioglitazone in Patients With Type 2 Diabetes on Hemodialysis
    Abe, Masanori
    Kikuchi, Fumito
    Okada, Kazuyoshi
    Matsumoto, Koichi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2009, 13 (03) : 238 - 239
  • [29] The therapeutic effect of erythropoietin on anemia in patients with type 2 diabetes mellitus
    Kim, D
    Ahn, C
    Nam, J
    Cha, BS
    Song, YD
    Lee, H
    Huh, K
    DIABETES, 2001, 50 : A96 - A96
  • [30] Impaired Erythropoietin Response to Intermittent Hypoxia in Patients with Type 2 Diabetes
    Wojan, Frank
    Stray-Gundersen, Sten
    Zhao, Jiahui
    Lalande, Sophie
    PHYSIOLOGY, 2023, 38